Acyldepsipeptide antibiotics

Enopeptin A

Acyldepsipeptide Antibiotics (ADEPs) are a class of antibiotics that have garnered significant interest for their unique mode of action against bacteria. Unlike traditional antibiotics that target bacterial cell wall synthesis, protein synthesis, or DNA replication, ADEPs target the ClpP protease, a key enzyme involved in protein degradation and regulation within the bacterial cell.

Mechanism of Action

ADEPs exert their antibacterial effects by binding to the ClpP protease, a component of the proteasome system in bacteria. Under normal conditions, ClpP requires the association with ClpX or ClpA, ATP-dependent chaperones, to recognize and degrade misfolded or unneeded proteins. However, when ADEPs bind to ClpP, they induce a conformational change that allows ClpP to degrade proteins indiscriminately without the need for its regulatory ATPase components. This uncontrolled protein degradation leads to bacterial cell death, making ADEPs a potent antibacterial agent.

Spectrum of Activity

ADEPs are primarily effective against Gram-positive bacteria, including resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). Their unique mechanism of action provides an advantage over traditional antibiotics, as it targets a less commonly exploited pathway in bacterial cells, reducing the likelihood of pre-existing resistance mechanisms.

Development and Challenges

The discovery of ADEPs and their potential as antibiotics has led to increased research and development efforts. However, there are challenges in the clinical development of ADEPs, including toxicity concerns and the development of resistance. Bacteria can develop resistance to ADEPs through mutations in the ClpP protease that prevent ADEP binding or through the overexpression of efflux pumps that remove ADEPs from the bacterial cell.

Clinical Applications

While ADEPs are still primarily in the research and development phase, their potential to address the growing problem of antibiotic resistance places them as a promising class of future antibiotics. Ongoing research aims to overcome the challenges associated with their development, with the hope that ADEPs can be used in combination with other antibiotics to treat resistant bacterial infections.

See Also

• Antibiotic resistance
• Proteasome inhibitor
• Bacterial protein degradation

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian